BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7858496)

  • 1. N- and K-ras oncogenes in plasma cell dyscrasias.
    Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
    Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
    Corradini P; Ladetto M; Voena C; Palumbo A; Inghirami G; Knowles DM; Boccadoro M; Pileri A
    Blood; 1993 May; 81(10):2708-13. PubMed ID: 8490179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
    Corradini P; Inghirami G; Astolfi M; Ladetto M; Voena C; Ballerini P; Gu W; Nilsson K; Knowles DM; Boccadoro M
    Leukemia; 1994 May; 8(5):758-67. PubMed ID: 8182933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
    Matozaki S; Nakagawa T; Nakao Y; Fujita T
    Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
    Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
    Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
    Fend F; Dogan A; Cook JR
    Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
    Chang H; Yeung J; Xu W; Ning Y; Patterson B
    Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin gene rearrangement in plasma cell dyscrasias: detection of small clonal cell populations in peripheral blood and bone marrow.
    Fend F; Weyrer K; Drach J; Schwaiger A; Umlauft F; Grünewald K
    Leuk Lymphoma; 1993 Jun; 10(3):223-9. PubMed ID: 8220121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
    Maura F; Petljak M; Lionetti M; Cifola I; Liang W; Pinatel E; Alexandrov LB; Fullam A; Martincorena I; Dawson KJ; Angelopoulos N; Samur MK; Szalat R; Zamora J; Tarpey P; Davies H; Corradini P; Anderson KC; Minvielle S; Neri A; Avet-Loiseau H; Keats J; Campbell PJ; Munshi NC; Bolli N
    Leukemia; 2018 Apr; 32(4):1044-1048. PubMed ID: 29209044
    [No Abstract]   [Full Text] [Related]  

  • 12. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
    Rasmussen T; Kuehl M; Lodahl M; Johnsen HE; Dahl IM
    Blood; 2005 Jan; 105(1):317-23. PubMed ID: 15339850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational landscape reflects the biological continuum of plasma cell dyscrasias.
    Rossi A; Voigtlaender M; Janjetovic S; Thiele B; Alawi M; März M; Brandt A; Hansen T; Radloff J; Schön G; Hegenbart U; Schönland S; Langer C; Bokemeyer C; Binder M
    Blood Cancer J; 2017 Feb; 7(2):e537. PubMed ID: 28234344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of chromosome 12p deletion in plasma cell dyscrasias.
    Jiang N; Qi C; Yu L; Ning Y; An G; Qiu L; Chang H
    Leuk Res; 2012 Jan; 36(1):32-6. PubMed ID: 21982640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
    Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
    Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
    Testa S; Kumar J; Goodell AJ; Zehnder JL; Alexander KM; Sidana S; Arai S; Witteles RM; Liedtke M
    Semin Oncol; 2022 Dec; 49(6):465-475. PubMed ID: 36503855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
    Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
    Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.